
    
      This study is designed to determine the safety and tolerability of Entinostat with
      Enzalutamide for treatment of patients with castration-resistant prostate cancer. There will
      be two dose levels of Entinostat in combination with same dose of Enzalutamide. Patients will
      be followed during treatment and 1 month post discontinuation.
    
  